Posted in M&A / Deals Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout April 1, 2026 Pharmaceutical Technology Biogen’s acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company’s portfolio of medicines. M&A / DealsRare DiseaseRead full story